Immune system

Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Friday, August 7, 2020 - 1:00pm

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 10:55 a.m. E.T.

Key Points: 
  • Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 10:55 a.m. E.T.
  • A live webcast of the presentation will be accessible in the Investor Relations section of the Aimmune website at www.aimmune.com .
  • Aimmune Therapeutics, Inc. is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies.
  • With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies.

Global HLA Typing Industry, Forecast to 2026 - Featuring Thermo Fisher Scientific, Omixon, CareDx, and QIAGEN Amongst Others

Thursday, August 6, 2020 - 9:45pm

The global HLA typing market is expected to reach USD 990.12 million by 2026 from USD 659.75 million in 2020, rising at a CAGR of ~7%.

Key Points: 
  • The global HLA typing market is expected to reach USD 990.12 million by 2026 from USD 659.75 million in 2020, rising at a CAGR of ~7%.
  • Majorly the increase in certain diseases such as blood cancers, genetic blood disorders where stem cell transplantation is required, this situation is expected to drive the HLA Typing market.
  • The global HLA (Human Leukocyte Antigen) Typing market is segmented based on end-user.
  • Globally, the HLA Typing market is growing at a CAGR of ~7.0% during the forecast period of 2020-2026.

Y-mAbs Announces Second Quarter 2020 Financial Results and Recent Corporate Developments

Thursday, August 6, 2020 - 9:01pm

NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the second quarter 2020.

Key Points: 
  • NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today reported financial results for the second quarter 2020.
  • We are very pleased with our second quarter 2020 financial results, especially seen in conjunction with the recent completion of our omburtamab BLA submission to the FDA.
  • We were very pleased to designate the first four SADA constructs for preclinical development and hope to file the first IND next year.
  • The Company will host a conference call on Friday, August 7, 2020 at 9 am eastern time.

Y-mAbs Announces Completion of Submission of Omburtamab Biologics License Application to FDA

Thursday, August 6, 2020 - 2:00pm

Omburtamab is an investigational, monoclonal antibody that targets B7-H3, an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types.

Key Points: 
  • Omburtamab is an investigational, monoclonal antibody that targets B7-H3, an immune checkpoint molecule that is widely expressed in tumor cells of several cancer types.
  • The omburtamab BLA is for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma.
  • I am excited to see the completion of Y-mAbs second BLA submission this year in neuroblastoma.
  • Researchers at Memorial Sloan Kettering Cancer Center (MSK) developed omburtamab, which is exclusively licensed by MSK to Y-mAbs.

SAB Biotherapeutics Awarded $35.6M from U.S. Department of Defense for COVID-19 and Scaling Rapid Response Antibody Program

Thursday, August 6, 2020 - 1:23pm

Our team is urgently and diligently executing on development and scaling to respond to the current coronavirus pandemic.

Key Points: 
  • Our team is urgently and diligently executing on development and scaling to respond to the current coronavirus pandemic.
  • We filed the Investigational New Drug (IND) application for SAB-185 in just 98 days from the initiation of the program, said Eddie J. Sullivan, co-founder, president and CEO of SAB Biotherapeutics.
  • About the DiversitAb Rapid Response Antibody Program:
    The Rapid Response Antibody Program was initiated as a $27 million progressive and competitive three-stage rapid response contract awarded by the U.S. Department of Defense (DoD).
  • SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies.

Cabaletta Bio Reports Second Quarter 2020 Financial Results and Provides Business Update 

Thursday, August 6, 2020 - 12:30pm

PHILADELPHIA, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced financial results for the second quarter ended June 30, 2020 and provided a business update.

Key Points: 
  • PHILADELPHIA, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced financial results for the second quarter ended June 30, 2020 and provided a business update.
  • In May 2020, in vivotarget engagement data was presented at the American Academy of Neurology 2020 Science Highlights Virtual Platform.
  • Cabaletta expects to initiate validation of cell processing for MuSK-CAART clinical trials with a commercial grade contract manufacturing partner in the second half of 2020.
  • Cabaletta will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 10, 2020 at 1:00 p.m.

BioNTech to Report Second Quarter 2020 Financial Results and Operational Update on August 11, 2020

Thursday, August 6, 2020 - 11:00am

A replay of the webcast will be available shortly after the conclusion of the call and archived on the Companys website for 30 days following the call.

Key Points: 
  • A replay of the webcast will be available shortly after the conclusion of the call and archived on the Companys website for 30 days following the call.
  • Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases.
  • The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.
  • Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

TRACON Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Wednesday, August 5, 2020 - 9:05pm

Envafolimab (KN035), a novel, single-domain antibody against PD-L1, is the first subcutaneously injected PD-(L)1 inhibitor to be studied in registrational trials.

Key Points: 
  • Envafolimab (KN035), a novel, single-domain antibody against PD-L1, is the first subcutaneously injected PD-(L)1 inhibitor to be studied in registrational trials.
  • The AR F877L mutation results in an alteration in the AR ligand binding domain that confers resistance to therapies for prostate cancer.
  • TRACON believes TRC253 can be developed and commercialized successfully in China and is actively seeking a strategic collaboration.
  • TRACON undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Xencor to Present at Upcoming Investor Conferences

Wednesday, August 5, 2020 - 9:01pm

Replays will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days.

Key Points: 
  • Replays will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days.
  • Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases.
  • Currently, 17 candidates engineered with Xencor's XmAb technology are in clinical development internally and with partners.
  • Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action.

GentiBio Launches with $20M Seed Funding from OrbiMed, Novartis Venture Fund and RA Capital Management, L.P. to Develop Engineered Regulatory T cells to Deliver Immune Tolerizing Therapies for Autoimmune and Inflammatory Diseases

Wednesday, August 5, 2020 - 12:00pm

Additionally, GentiBio's platform will enable the scaled production of robust EngTregs cell therapy products that are antigen specific and tunable.

Key Points: 
  • Additionally, GentiBio's platform will enable the scaled production of robust EngTregs cell therapy products that are antigen specific and tunable.
  • "Tregs are rare cells within the immune system and current therapies that source Tregs cells from the blood stream can be costly and cumbersome.
  • "This partnership with GentiBio is an important step forward in identifying and improving novel treatments for autoimmune diseasesa key goal of the Benaroya Research Institute.
  • An internationally recognized medical research institute, BRI accelerates discovery through laboratory breakthroughs in immunology that are translated to clinical therapies.